Clinical aggression of prolactinomas: Correlations with invasion and recurrence

Romanian Journal of Morphology and Embryology

Volumn 54, Issue 4, 2013, Pages 1075-1080

  Popescu, Mihaela N ^a   Ionescu, Elena ^a   Iovanescu L C ^a   Cotoi, B V ^a   Popescu, A I ^a   Gǎnescu, Anca Elena ^b   Glodeanu, Adina ^a   Geormǎneanu, Cristiana ^a   Moraru, Andreiana ^c   Pǎtraşcu, Anca ^a  

^a UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

^b UNIVERSITY OF CRAIOVA   (Romania)

^c Floreasca Emergency Hospital   (Romania)

Author keywords

Immunohistochemistry; Invasiveness; Prolactinomas

Indexed keywords

CYCLINE; KI 67 ANTIGEN; PROLACTIN; PROTEIN P53;

ADENOMA; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHILD; HUMAN; HYPOPHYSIS TUMOR; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROLACTINOMA; TUMOR INVASION; TUMOR RECURRENCE; TUMOR VOLUME; YOUNG ADULT;

ADENOMA; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CHILD; HUMANS; KI-67 ANTIGEN; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA; PROLIFERATING CELL NUCLEAR ANTIGEN; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84891602825     PISSN: 12200522     EISSN: 20668279     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Mastronardi L, Guiducci A, Spera C, Puzzilli F, Liberati F, Maira G, Ki-67 labelling index and invasiveness among anterior pituitary adenomas: analysis of 103 cases using the MIB-1 monoclonal antibody, J Clin Pathol, 1999, 52(2):107-111.
2. Kumar V, Abbas AK, Fausto N, Mitchell RN (eds), Robbins and Cotran basic pathology, 8th edition, Elsevier, Philadelphia, USA, 2007, 860-882.
3. Kovacs K, Horvath E, The differential diagnosis of lesions involving the sella turcica, Endocr Pathol, 2001, 12(4):389-395.
4. Wang AT, Mullan RJ, Lane MA, Hazem A, Prasad C, Gathaiya NW, Fernández-Balsells MM, Bagatto A, Coto- Yglesias F, Carey J, Elraiyah TA, Erwin PJ, Gandhi GY, Montori VM, Murad MH, Treatment of hyperprolactinemia: a systematic review and meta-analysis, Syst Rev, 2012, 1:33.
5. Peña KS, Rosenfeld JA, Evaluation and treatment of galactorrhea, Am Fam Physician, 2001, 63(9):1763-1770.
6. Serri O, Chik CL, Ur E, Ezzat S, Diagnosis and management of hyperprolactinemia, Can Med Assoc J, 2003, 169(6):575-581.
7. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A, Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas, Clin Endocrinol (Oxf), 2006, 65(2):265-273.
8. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA; Endocrine Society, Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab, 2011, 96(2):273-288.
9. Babey M, Sahli R, Vajtai I, Andres RH, Seiler RW, Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists, Pituitary, 2011, 14(3):222-230.
10. Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER Jr, p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions, Neurosurgery, 1996, 38(4):765-770; discussion 770-771.
11. Gözü H, Bilgiç B, Hazneci J, Sargin H, Erkal F, Sargin M, Sönmez B, Orbay E, Şeker M, Bozbuǧa M, Bayindir Ç, Is Ki-67 index a useful labeling marker for invasion of pituitary adenomas? Turk J Endocrinol Metab, 2005, 9(4):107-113.
12. Ogawa Y, Ikeda H, Tominaga T, Clinicopathological study of prognostic factors in patients with pituitary adenomas and Ki-67 labeling index of more than 3%, J Endocrinol Invest, 2009, 32(7):581-584.
13. Pawlikowski M, Gruszka A, Kurnatowska I, Winczyk K, Kunert-Radek J, Radek A, Proliferating cell nuclear antigen (PCNA) expression in pituitary adenomas: relationship to the endocrine phenotype of adenoma, Folia Histochem Cytobiol, 2006, 44(1):37-41.
14. Yu R, Heaney AP, Lu W, Chen J, Melmed S, Pituitary tumor transforming gene causes aneuploidy and p53-dependent and p53-independent apoptosis, J Biol Chem, 2000, 275(47): 36502-36505.
15. Kane LA, Leinung MC, Scheithauer BW, Bergstralh EJ, Laws ER Jr, Groover RV, Kovacs K, Horvath E, Zimmerman D, Pituitary adenomas in childhood and adolescence, J Clin Endocrinol Metab, 1994, 79(4):1135-1140.
16. Catli G, Abaci A, Bober E, Büyükgebiz A, Clinical and diagnostic characteristics of hyperprolactinemia in childhood and adolescence, J Pediatr Endocrinol Metab, 2013, 26(1-2): 1-11.
17. Cannavò S, Venturino M, Curtò L, De Menis E, D'Arrigo C, Tita P, Billeci D, Trimarchi F, Clinical presentation and outcome of pituitary adenomas in teenagers, Clin Endocrinol (Oxf), 2003, 58(4):519-527.
18. Tǎnase C, Codreanu E, Ardeleanu C, Terzea D, Ciubotaru V, Ogrezean I, Cruceru ML, Popescu M, Significance of some proliferating cell markers in predicting pituitary adenomas behavior, 10th Meeting of the European Neuroendocrine Association (ENEA), Munich, 12.-14. September, 2002, 92.